Ad5-3delta-A20T

N/A

Report date: 2025/03/14 16:24:00

Base Information

Drug NameAd5-3delta-A20T
Drug Alias Nameoncolytic adenovirus therapy targeting alpha5-beta6 integrins (Barts Cancer Institute)
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionIntegrin alpha-V/beta-6 modulators
TargetsIntegrin alpha-V/beta-6
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCancer Research UK Barts Centre
China Registration ClassN/A

Develop Information

Active CompaniesCancer Research UK Barts Centre
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A